Heparin-induced thrombocytopenia: An overview

Blood Reviews

Volumn 16, Issue 1, 2002, Pages 77-80

  Kelton, J G ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; FC RECEPTOR; HEPARIN; HEPARIN ANTAGONIST; HIRUDIN; IMMUNOGLOBULIN G; THROMBOCYTE FACTOR 4;

ANTIGEN ANTIBODY COMPLEX; CLINICAL FEATURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; HEPARINIZATION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHORT SURVEY; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0036213008     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0189     Document Type: Article

References (27)

1. Heparin-induced immune thrombocytopenia
2. Heparin-induced thrombocytopenia: Laboratory studies
3. Impact of the patient population on the risk for heparin-induced thrombocytopenia
4. Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia
5. Heparin-induced thrombocytopenia: Minimizing the risks in the elderly patient
6. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
7. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
8. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
9. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
10. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia
11. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation
12. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia
13. Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome
14. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications - A review
15. Laboratory diagnosis of heparin- associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay
16. Laboratory diagnosis of heparin-induced thrombocytopenia
17. Heparin-induced thrombocytopenia: Laboratory diagnosis and management
18. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
19. Venous thromboembolism in heparin-induced thrombocytopenia
20. A 14-year study of heparin-induced thrombocytopenia
21. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia
22. Heparin-induced thrombocytopenia (HIT): In vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin)
23. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
24. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor
25. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome
26. Anticoagulation with Novastan (argatroban) in patients with heparin-nduced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
27. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in-patients with HIT